Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure

Trial Profile

Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Sildenafil (Primary)
  • Indications Chronic heart failure; Pulmonary hypertension
  • Focus Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2016 Planned End Date changed from 1 Feb 2015 to 1 May 2017, according to ClinicalTrials.gov record.
    • 14 Mar 2016 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top